IDC MarketScape Names Medidata a Leader in Life Science R&D Risk-Based Monitoring Solutions Vendor Assessment
6.2.2023 21:15:00 EET | Business Wire | Press release
Medidata, a Dassault Systèmes company, announced it has been positioned as a Leader in the IDC MarketScape “Worldwide Life Science R&D Risk-Based Monitoring Solutions 2022 Vendor Assessment (doc #US48061722).” The IDC MarketScape assessment evaluated Medidata’s comprehensive RBQM (Risk-Based Quality Management) capabilities including Medidata Detect, which provides clinical operations teams with the ability to proactively monitor and mitigate risks to data integrity and patient safety.
“Our position in the IDC MarketScape comes from the success our customers gain with Medidata’s industry-leading analytics, Detect, and our Professional Services offering,” said Fareed Melhem, senior vice president, Medidata AI. “Clinical trials are faster and have vastly more data than ever before, requiring a seismic shift in how clinical operations and data management teams can–and should–monitor and analyze those data to derive actionable insights.”
Medidata Detect is the end-to-end data and risk surveillance platform, providing cross-functional operational teams with the ability to identify, document, monitor, and mitigate risks to data integrity, and patient safety. Detect users have access to role-based activities and workflows supported by real-time data, visualizations, and automated insights for better planning and increased efficiency.
As with all of its solutions, RBQM customers are supported by the Medidata Professional Services team – recognized experts with deep clinical trial expertise. The team supports rapid implementation and client enablement, process improvements, change management, business transformation, and plays a critical role in ROI maximization.
About the IDC MarketScape
The IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005505/en/
Contact information
Tom Paolella
Senior Director, Corporate Communications & Affairs
+1-848-203-7596
thomas.paolella@3ds.com
Paul Oestreicher
External Communications Director
+1-917-522-4692
paul.oestreicher@3ds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results13.5.2026 09:38:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER). Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth. Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amortization expenses for VYVANSE and lower restructuring expenses. Core EPS increased by 5.2% YoY at AER and by 3.1% at CER, while reported EPS increased by 78.1% YoY. Adjusted Fre
Allianz Delivers Record Operating Profit in Strong Start to 202613.5.2026 08:20:00 EEST | Press release
1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net income advances by 48.4 percent to 3.8 billion euros, impacted by the sale of the stakes in our Indian Joint Ventures. Underlying growth, which adjusts for the sale effects and offsetting measures, is strong at 7 percent2Core earnings per share grow 50.7 percent and reach 9.96 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 9 percent 2Annualized core RoE at 24.2 percent, underlying level very strong at 18 percent 2Solvency IIratio3 increases by 2 percentage points to 221 percent4. Capital generation was st
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca13.5.2026 08:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca’s IT infrastructure and decision workflows. The new agents' functionality is intended to help AstraZeneca’s decision-making teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis within established governance, security, and enterprise standards. "At Owkin, we believe the future of the pharmaceutical industry is agentic," said Thomas Clozel, CEO and co-founder of Owkin. "Our exper
Abu Dhabi's Phoenix Group Partners with DC Max to Unlock $8 Billion European AI Data Center Opportunity, with Lyon, France as First Deployment13.5.2026 08:00:00 EEST | Press release
Phoenix Group PLC (ADX: PHX), an IHC portfolio company and global digital infrastructure operator, today announced a strategic partnership with DC Max to develop its first European AI data center, an 18MW facility in Lyon, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512531777/en/ From left to right: Matthias Luecker, Chairman of DC Max, and Munaf Ali, Co-Founder and Group CEO of Phoenix Group, during the signing ceremony for the strategic partnership between Phoenix Group and DC Max to launch a European AI infrastructure platform anchored by the company’s first deployment in Lyon, France. (Photo: AETOSWire) The project is the inaugural deployment of Phoenix's European Data Center Platform, a scalable framework targeting over 1GW of combined AI and HPC capacity across Europe and the GCC. Phoenix sees this move as a direct extension of the UAE’s national AI ambition, an Abu Dhabi-headquartered company bringing it
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim12.5.2026 20:39:00 EEST | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. “We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents,” said Dr. Arno Riße, Angel’s attorney at the Arnold Ruess law firm of Düsseldorf. “We are grateful that the court decided not to grant Align's request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.” “We categorically deny the allegations of i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom